Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced its plans for 2010 aimed at advancing the clinical development of its high-value drug development pipeline and enhancing shareholder value.

22 Jan 2010

Panel discussion on benefits of oral chemotherapy in cancer care

US Oncology, Inc. partnered with the Association of Community Cancer Centers, Association of Oncology Social Work, American Society for Clinical Oncology, Community Oncology Alliance, Oncology Nursing Society and the National Patient Advocate Foundation in hosting a panel discussion on Capitol Hill today to examine the benefits of oral chemotherapy in cancer care, as well as challenges in its prescribing, accessibility and adherence in the current health care system.

22 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

ChromoCure's aneuploidy theory of cancer further validated

ChromoCure, Inc. -- The Company announces that its long-held theory of cancer, aneuploidy, has been further validated by a study published in the January 15, 2010 issue of Cancer Research (Volume 70, Issue 2).

21 Jan 2010

Medco Health Solutions launches Medco TRC for oncology patients

Medco Health Solutions, Inc. today announced the launch of the Medco Therapeutic Resource Center® (TRC) for oncology patients headquartered in Whitestown, Ind., where specialist pharmacists will manage the company's more than 850,000 patients currently living with cancer, one of the fastest growing segments of healthcare.

21 Jan 2010

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Ipsen and Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that they have entered into a partnership to create a world leading hemophilia franchise. The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Healthcare industry in Asia Pacific to grow up to US$349 billion by 2012

Frost & Sullivan believes that the healthcare industry is undergoing a paradigm shift from "sickness care" to "wellness". Focused on the 5 Ps – Preventive, Pre-emptive, Personalized, Predictive and Personal Responsibility – the healthcare industry in Asia Pacific is expected to grow to US$349 billion by 2012.

21 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

Xbrane Bioscience signs licensing arrangement with Vaxiion Therapeutics

The Swedish biotech company Xbrane Bioscience and the San Diego based biotech company Vaxiion Therapeutics, Inc. have announced that they have reached a licensing arrangement granting Xbrane Bioscience rights to Vaxiion’s proprietary protein production system – the Rhamex System™.

21 Jan 2010

First Coast Oncology uses PEM scanner and AccuBoost image guided procedure for breast cancer treatment

First Coast Oncology in Jacksonville, Florida has significantly enhanced its ability to treat breast cancer with the addition of a Naviscan PEM (Positron Emission Mammography) scanner.

20 Jan 2010

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today that it has raised $10 million in investments and related payments from an affiliate of Celtic Therapeutics Holdings L.P. (“Celtic Therapeutics”) and Tichenor Ventures, LLC.

20 Jan 2010

Modern healthcare in Tri-Cities offers bright economic future and improved quality of life

Reliable, modern healthcare is Tri-Cities, Tennessee's "ace in the hole" when it comes to future economic development and improved quality of life.

20 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

$SIR supports use of vertebral augmentation for patients with spine fractures$

SIR supports use of vertebral augmentation for patients with spine fractures

Given the current controversy over vertebroplasty-a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy-what's a patient to do?

20 Jan 2010

Gene study could result in personalized therapies for patients with deadly brain cancer

New findings by researchers at UNC Lineberger Comprehensive Cancer Center suggest that the most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is probably not a single disease but a set of diseases, each with a distinct underlying molecular disease process.

20 Jan 2010

Oncology News and Research

Further Reading

CytRx announces its plans to advance multiple oncology development programs in 2010

Panel discussion on benefits of oral chemotherapy in cancer care

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

MDRNA to receive European patent for its intranasal insulin formulation

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

ChromoCure's aneuploidy theory of cancer further validated

Medco Health Solutions launches Medco TRC for oncology patients

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Healthcare industry in Asia Pacific to grow up to US$349 billion by 2012

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

Xbrane Bioscience signs licensing arrangement with Vaxiion Therapeutics

First Coast Oncology uses PEM scanner and AccuBoost image guided procedure for breast cancer treatment

Kolltan Pharmaceuticals raises $10M for advancing its therapeutic development pipeline

Modern healthcare in Tri-Cities offers bright economic future and improved quality of life

Health Canada approves Novartis' Afinitor to treat patients with mRCC

SIR supports use of vertebral augmentation for patients with spine fractures

Gene study could result in personalized therapies for patients with deadly brain cancer

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News